Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda

Sporadic porphyria cutanea tarda (PCT) is strongly associated with HCV infection in our population ^1,2,3,4. . Therapeutic options for PCT include phlebotomies and low-dose 4-aminoquinolines, which show high rates of disease remission. However, some PCT patients may present frequent relapses attributable to resistance/intolerability/poor adherence to conventional treatments and/or persistence of risk factors. In 2014 we reported the first case of a patient with active PCT and HCV-HIV co-infection cured with direct antiviral agents (DAAs) ⁵. Herein, we present a larger cohort of patients, demonstrating the rapid and persistent remission of PCT with DAAs regimes administered for HVC infection.

This article is protected by copyright. All rights reserved.

http://ift.tt/2ngKdwx